

Freedom of Information Request

Ref: UHB 19-559

17 September 2019

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

Numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the following conditions.

Please note that the Trust was able to split patients to the below three categories:

Any patients for rheumatology indications are under Rheumatoid Arthritis.

Any patients for dermatology indications are under Psoriasis.

Any patients for gastroenterology indications are under Crohns disease.

Treatment	Total	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)	43	43	0	0
Adalimumab biosimilar [Amgevita]	123	62	2	59
Adalimumab biosimilar [Hulio]	0	0	0	0
Adalimumab [Humira]	510	178	108	224
Adalimumab biosimilar [Hyrimoz]	0	0	0	0
Adalimumab biosimilar [Imraldi]	517	164	150	203
Apremilast (Otezla)	36	5	31	0
Baricitinib (Olumiant)	39	38	1	0
Brodalumab (Kyntheum)	1	0	1	0
Certolizumab (Cimzia)	25	24	0	1
Dimethyl Fumarate (Skilarence)	12	0	12	0
Etanercept (Enbrel)	15	12	3	0

Etanercept Biosimilar (Benepali)	212	157	55	0
Etanercept Biosimilar (Erelzi)	0	0	0	0
Golimumab (Simponi)	37	31	0	6
Guselkumab (Tremfya)	1	0	1	0
Infliximab [Flixabi]	0	0	0	0
Infliximab [Inflectra]	251	40	6	205
Infliximab [Remicade]	14	13	0	1
Infliximab [Remsima]	0	0	0	0
Ixekizumab (Taltz)	13	2	11	0
Rituximab (Mabthera)	2	2	0	0
Rituximab Biosimilar (Rixathon)	0	0	0	0
Rituximab Biosimilar (Truxima)	54	53	1	0
Sarilumab (Kevzara)	0	0	0	0
Secukinumab (Cosentyx)	57	24	33	0
Tildrakizumab (Ilumetri)	0	0	0	0
Tocilizumab (Ro Actemra)	53	53	0	0
Tofacitinib (Xeljanz)	20	5	0	15
Ustekinumab (Stelara)	138	6	74	58
Vedolizumab (Entyvio)	100	0	0	100

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary
University Hospitals Bristol NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

FOI Team
UH Bristol NHS Foundation Trust